Nanoparticles Help to Enhance Lung Cancer PD-L1 Inhibitors
| Date | 26th, Jul 2022 |
|---|---|
| Source | AZoNano - Nanotechnology Websites |
DESCRIPTION
PD-L1 and PD-1 are immune checkpoints that control signal pathways associated with T-cell activation. Previously, scientists targeted the PD-1/PD-L1 axis with immune checkpoint inhibitors (ICIs) in patients with advanced non-small cell lung cancer (NSCLC).